Company Encyclopedia
View More
name
Cabaletta Bio
CABA.US
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc.
1.946 T
CABA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)

    Jefferies analyst Roger Song maintains a Buy rating for Cabaletta Bio with a $14.00 price target. The analyst consensus is a Strong Buy with an average price target of $17.83. Song, who covers the Healthcare sector, has an average return of -5.1% and a 37.50% success rate on recommended stocks.

    Tip Ranks·
    US
    CABA
    +2.40%
    Tip Ranks·
    US
    CABA
    +2.40%

    Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

    Guggenheim analyst Yatin Suneja reiterated a Buy rating for Cabaletta Bio with a $15.00 price target. The stock closed at $2.45, indicating significant upside potential. Suneja, a 5-star analyst, has a 21.2% average return and a 55.18% success rate. The consensus among analysts is a Strong Buy with a $17.83 average price target, suggesting a 627.76% upside. H.C. Wainwright also reiterated a Buy rating with a $16.00 price target.

    Tip Ranks·
    US
    CABA
    +2.40%
    Tip Ranks·
    US
    CABA
    +2.40%

    Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

    H.C. Wainwright analyst Douglas Tsao has reiterated a Buy rating on Cabaletta Bio (CABA) with a price target of $16.00. Tsao, a 5-star analyst, has an average return of 22.0% and a success rate of 53.85%. The analyst consensus for Cabaletta Bio is a Strong Buy, with a price target consensus of $18.40.

    Tip Ranks·
    US
    CABA
    +2.40%
    Tip Ranks·
    US
    CABA
    +2.40%

    Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

    William Blair analyst Sami Corwin has maintained a Buy rating on CABA stock due to Cabaletta Bio's promising clinical progress and strategic advancements. The company reported encouraging results from its RESET trials in autoimmune diseases, particularly in dermatomyositis and antisynthetase syndrome. Cabaletta has also secured key regulatory designations and appointed Steve Gavel as chief commercial officer, enhancing its commercial strategy. Cantor Fitzgerald also supports a Buy rating with a $30 price target.

    Tip Ranks·
    US
    CABA
    +2.40%
    Tip Ranks·
    US
    CABA
    +2.40%

    Cabaletta Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    CABA
    +2.40%
    LB filings·
    US
    CABA
    +2.40%
    © 2025 Longbridge｜Disclaimer